دورية أكاديمية
Diagnostic value of sphingolipid metabolism-related genes CD37 and CXCL9 in nonalcoholic fatty liver disease.
| العنوان: | Diagnostic value of sphingolipid metabolism-related genes CD37 and CXCL9 in nonalcoholic fatty liver disease. |
|---|---|
| المؤلفون: | Zhang J; Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Wang L; The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Jiang M; The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. |
| المصدر: | Medicine [Medicine (Baltimore)] 2024 Feb 23; Vol. 103 (8), pp. e37185. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins |
| مواضيع طبية MeSH: | Non-alcoholic Fatty Liver Disease*/genetics, Humans ; Lipid Metabolism ; Cell Movement ; Databases, Factual ; Immunoproteins ; Biomarkers ; Computational Biology ; Chemokine CXCL9 ; Antigens, Neoplasm ; Tetraspanins |
| مستخلص: | The development of nonalcoholic fatty liver disease (NAFLD) has been reported to be caused by sphingolipid family inducing insulin resistance, mitochondrial dysfunction, and inflammation, which can be regulated by multiple sphingolipid metabolic pathways. This study aimed to explore the molecular mechanism of crucial sphingolipid metabolism related genes (SMRGs) in NAFLD. Firstly, the datasets (GSE48452, GSE126848, and GSE63067) from the Gene Expression Omnibus database and sphingolipid metabolism genes (SMGs) from previous research were collected for this study. The differentially expressed genes (DEGs) between different NAFLD and controls were acquired through "limma," and the SMRGs were authenticated via weighted gene co-expression network analysis (WGCNA). After overlapping the DEGs and SMRGs, the causality between the intersection genes (DE-SMRGs) and NAFLD was explored to sort out the candidate biomarkers by Mendelian randomization (MR) study. The receiver operating characteristic (ROC) curves of candidate biomarkers in GSE48452 and GSE126848 were yielded to determine the biomarkers, followed by the nomogram construction and enrichment analysis. Finally, the immune infiltration analysis, the prediction of transcription factors (TFs) and drugs targeting biomarkers were put into effect. A total of 23 DE-SMRGs were acquired based on the differential analysis and weighted gene co-expression network analysis (WGCNA), of which 3 DE-SMRGs (CD37, CXCL9 and IL7R) were picked out for follow-up analysis through univariate and multivariate MR analysis. The values of area under ROC curve of CD37 and CXCL9 were >0.7 in GSE48452 and GSE126848, thereby being regarded as biomarkers, which were mainly enriched in amino acid metabolism. With respect to the Spearman analysis between immune cells and biomarkers, CD37 and CXCL9 were significantly positively associated with M1 macrophages (P < .001), whose proportion was observably higher in NAFLD patients compared with controls. At last, TFs (ZNF460 and ZNF384) of CD37 and CXCL9 and a total of 79 chemical drugs targeting CD37 and CXCL9 were predicted. This study mined the pivotal SMRGs, CD37 and CXCL9, and systematically explored the mechanism of action of both biomarkers based on the public databases, which could tender a fresh reference for the clinical diagnosis and therapy of NAFLD. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.) |
| References: | Leukemia. 2002 Sep;16(9):1596-602. (PMID: 12200669) Math Biosci Eng. 2019 Nov 22;17(2):1381-1395. (PMID: 32233584) Drug Metab Rev. 2023 Aug;55(3):163-180. (PMID: 37042420) BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831) J Hepatol. 2023 Aug;79(2):538-551. (PMID: 36893854) Clin Res Cardiol. 2021 Jul;110(7):921-937. (PMID: 32696080) Int J Mol Sci. 2020 Dec 15;21(24):. (PMID: 33333768) BMC Gastroenterol. 2013 Jul 23;13:120. (PMID: 23875831) Genet Epidemiol. 2016 May;40(4):304-14. (PMID: 27061298) Exp Cell Res. 2021 Oct 15;407(2):112801. (PMID: 34461107) Clin Liver Dis. 2011 May;15(2):223-43, vii-x. (PMID: 21689610) Liver Int. 2007 May;27(4):440-50. (PMID: 17403183) Expert Opin Investig Drugs. 2018 Feb;27(2):171-177. (PMID: 29323537) Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. (PMID: 34508238) PLoS One. 2015 May 20;10(5):e0124544. (PMID: 25993042) Prog Lipid Res. 2014 Apr;54:53-67. (PMID: 24513486) Innovation (Camb). 2021 Jul 01;2(3):100141. (PMID: 34557778) Cell Metab. 2021 Jul 6;33(7):1293-1306. (PMID: 34233172) Liver Int. 2020 Jun;40(6):1254-1261. (PMID: 32301554) Int J Epidemiol. 2017 Dec 1;46(6):1985-1998. (PMID: 29040600) Cell Metab. 2013 Aug 6;18(2):296-302. (PMID: 23931760) Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295) Biosci Rep. 2020 May 29;40(5):. (PMID: 32400873) Elife. 2018 May 30;7:. (PMID: 29846171) Gastroenterology. 2017 Jul;153(1):233-248.e16. (PMID: 28363640) J Hepatol. 2021 Nov;75(5):1042-1048. (PMID: 34289397) Eur J Epidemiol. 2015 Jul;30(7):543-52. (PMID: 25773750) Clin Transl Med. 2017 Dec;6(1):26. (PMID: 28755163) Biochem Pharmacol. 2007 May 1;73(9):1340-6. (PMID: 17239824) Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) Hepatology. 2018 Jan;67(1):328-357. (PMID: 28714183) J Cell Physiol. 2019 Feb;234(2):1851-1861. (PMID: 30067865) Int J Mol Sci. 2023 Mar 29;24(7):. (PMID: 37047411) Thyroid. 2019 Sep;29(9):1173-1191. (PMID: 31389309) Exp Ther Med. 2019 Dec;18(6):4845-4851. (PMID: 31772648) Hepatol Commun. 2022 Jan;6(1):77-89. (PMID: 34558849) PeerJ. 2023 Apr 11;11:e15225. (PMID: 37065701) Ann Transl Med. 2021 Oct;9(20):1598. (PMID: 34790804) Int J Biol Sci. 2023 Jan 1;19(1):311-330. (PMID: 36594091) Cardiovasc Diabetol. 2015 Dec 18;14:153. (PMID: 26682540) Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. (PMID: 30653341) Front Immunol. 2023 Jul 03;14:1202725. (PMID: 37465666) Nat Rev Endocrinol. 2022 Aug;18(8):461-472. (PMID: 35534573) Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253) Int Immunopharmacol. 2021 Aug;97:107823. (PMID: 34102486) Front Endocrinol (Lausanne). 2022 Dec 08;13:1056310. (PMID: 36568076) Chin Med J (Engl). 2022 May 20;135(10):1163-1171. (PMID: 35788089) Rev Esp Cardiol. 2011 Jun;64(6):501-7. (PMID: 21531065) J Hepatol. 2020 Jul;73(1):202-209. (PMID: 32278004) Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943) BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208) Adv Exp Med Biol. 2020;1231:45-51. (PMID: 32060845) Int J Mol Sci. 2022 Apr 13;23(8):. (PMID: 35457142) Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1102-17. (PMID: 27173510) Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):460-469. (PMID: 29066349) Biochimie. 2019 Apr;159:9-22. (PMID: 30071259) Methods Mol Biol. 2018;1711:243-259. (PMID: 29344893) BMC Endocr Disord. 2022 Mar 14;22(1):63. (PMID: 35287643) Front Endocrinol (Lausanne). 2021 Mar 18;12:635175. (PMID: 33815291) Cell Metab. 2007 Mar;5(3):167-79. (PMID: 17339025) BMC Bioinformatics. 2008 Dec 29;9:559. (PMID: 19114008) Nat Rev Cancer. 2018 Jan;18(1):33-50. (PMID: 29147025) Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191. (PMID: 29165427) J Am Soc Nephrol. 2016 Nov;27(11):3253-3265. (PMID: 27486138) Hepatology. 2014 Jul;60(1):224-36. (PMID: 24700550) iScience. 2021 Oct 09;24(11):103249. (PMID: 34755091) Front Endocrinol (Lausanne). 2019 Sep 26;10:665. (PMID: 31616384) Hepatology. 2018 Jan;67(1):145-158. (PMID: 28802074) Sci Transl Med. 2020 Dec 2;12(572):. (PMID: 33268508) Nat Med. 2018 Jul;24(7):908-922. (PMID: 29967350) Front Endocrinol (Lausanne). 2023 Jan 04;13:1034494. (PMID: 36686439) J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6. (PMID: 23632345) J Diabetes Res. 2020 Jul 31;2020:3920196. (PMID: 32832560) Hepatology. 2023 Mar 1;77(3):949-964. (PMID: 35971878) Free Radic Biol Med. 2021 May 1;167:66-80. (PMID: 33705961) Front Immunol. 2022 Nov 08;13:1038401. (PMID: 36426356) |
| المشرفين على المادة: | 0 (Immunoproteins) 0 (Biomarkers) 0 (CXCL9 protein, human) 0 (Chemokine CXCL9) 0 (CD37 protein, human) 0 (Antigens, Neoplasm) 0 (Tetraspanins) |
| تواريخ الأحداث: | Date Created: 20240223 Date Completed: 20240226 Latest Revision: 20240810 |
| رمز التحديث: | 20240812 |
| مُعرف محوري في PubMed: | PMC11309649 |
| DOI: | 10.1097/MD.0000000000037185 |
| PMID: | 38394483 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!